AstraZeneca stock trades at EUR 146.98 as UBS cuts its target

Published on 09/29/2026 at 14:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock was at EUR 146.98 at Lang & Schwarz on September 29, 2026, plus 0.57 percent versus EUR 146.15. H1 revenue rose 6 percent.

Wissenschaftler im weißen Kittel arbeiten in modernem Pharma-Forschungslabor — AstraZeneca plc (ISIN GB0009895292) betreibt moderne Forschungslabore für pharmazeutische Wirkstoffentwicklung und klinische Studien weltweit, Illustration mit AI erstellt.

AstraZeneca stock (ISIN GB0009895292) was trading at EUR 146.98 at Lang & Schwarz on September 29, 2026, plus 0.57 percent versus the prior close of EUR 146.15. The company's investor-relations calendar lists Santander Pharma Day for September 29, while recent analyst revisions keep attention on valuation and pipeline execution.

UBS trims its price target

According to Interactive Investor on September 16, 2026, UBS lowered its AstraZeneca price target from GBp 17,600 to GBp 15,200 and retained a Buy rating. The same report said Berenberg set a GBp 15,000 target and highlighted a 13 percent return on research and development investment for AstraZeneca's current pipeline cohort.

The revisions frame the stock around delivery rather than a single clinical readout. UBS said AstraZeneca remained on track for its USD 80 billion medium-term revenue target, while the report also cited a USD 82 billion sales view for 2030.

H1 growth sets the earnings base

AstraZeneca reported USD 14.1 billion of total revenue for the first half of 2026, up 6 percent year over year, according to Scanx on September 17, 2026. Revenue growth reached 11 percent when excluding generic pressure on Farxiga and Brilinta, while core EPS increased 11 percent.

Scanx also reported that AstraZeneca reiterated full-year guidance for total revenue growth in the mid- to high-single-digit range and core EPS growth in the low double digits. That comparison gives the September analyst debate a measurable operating base.

Investor calendar adds the next date

AstraZeneca's official results page lists its H1 and Q2 2026 results on July 27, 2026, and an upcoming Barclays Cardio Pipeline Investor Call on October 5, 2026. The company also listed its Santander Pharma Day appearance for September 29, 2026, in its AstraZeneca investor calendar.

AstraZeneca stock holds its level

AstraZeneca stock was trading at EUR 146.98 at Lang & Schwarz on September 29, 2026, at 2:02 p.m. CEST, plus 0.57 percent versus the prior close of EUR 146.15. The primary listing is on the London Stock Exchange, where the ordinary shares carry ISIN GB0009895292, according to an RNS notice dated September 1, 2026, published through Nasdaq.